Clinical Trial Update: Saizen in Intra-uterine Growth Retardation [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for Saizen (somatropin) in children born with intrauterine growth restriction; the study completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrauterine Growth Restriction

Drugs mentioned

• Saizen (somatropin)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Children Born With Serious Intra-uterine Growth Retardation | Phase 3 | Status: COMPLETED | Results posted: 2012-09-25